<p>尽管 <strong>Cawachi Limited</strong>（东京证券交易所代码：2664）上周的财报数据良好，但市场似乎对此反应平平。我们进行了一些分析，试图找出原因，并认为投资者可能忽视了财报中一些令人鼓舞的因素。</p>
<p>人工智能即将改变医疗保健。这 20 只股票正在从早期诊断到药物发现等各个方面进行研发。最棒的是——它们的市值都在 100 亿美元以下——现在仍然有机会提前布局。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/5478544-earnings-and-revenue-history-1-dark-2/1762379223725?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/5478544-earnings-and-revenue-history-1-dark-2/1762379223725"/></p>
<p>东京证券交易所：2664 财报和收入历史 2025 年 11 月 5 日</p>
<h2>非常规项目对利润的影响</h2>
<p>重要的是，我们的数据表明，Cawachi 去年的利润因非常规项目减少了 12 亿日元。虽然由于非常规项目的扣除在第一时间令人失望，但也有积极的一面。我们查看了数千家上市公司，发现非常规项目通常是一次性的。而且，毕竟，这正是会计术语所暗示的。假设这些非常规支出不会再次出现，我们因此预计 Cawachi 明年的利润会更高，其他条件不变。</p>
<p><strong>注意：</strong> 我们始终建议投资者检查资产负债表的强度。点击这里查看我们对 Cawachi 的资产负债表分析。</p>
<h2>我们对 Cawachi 利润表现的看法</h2>
<p>非常规项目（支出）在过去一年中削弱了 Cawachi 的收益，但我们可能会在明年看到改善。基于这一观察，我们认为 Cawachi 的法定利润实际上低估了其盈利潜力！而且过去三年每股收益年增长 5.5%。当然，在分析其收益时，我们才刚刚开始；还可以考虑利润率、预测增长和投资回报等其他因素。如果你想更深入地了解 Cawachi，还需要关注它目前面临的风险。为此，我们发现了 <strong>2 个警示信号</strong>（其中 1 个不容忽视！），在购买 Cawachi 的任何股票之前，你应该了解这些。</p>
<p>这份报告仅关注了一个因素，揭示了 Cawachi 利润的性质。但如果你能够专注于细节，总会有更多的发现。有些人认为高股本回报率是优质企业的良好标志。因此，你可能希望查看这份 <strong>免费</strong> 的高股本回报率公司集合，或这份高内部持股的股票列表。</p>

2664

<p>Cawachi Limited（东京证券交易所代码：2664）报告了令人鼓舞的收益，但市场反应却平淡。分析师建议，投资者可能会忽视收益报告中的积极方面，特别是一些异常支出对利润造成了 12 亿日元的影响。这些异常项目通常是一次性事件，表明明年利润有改善的潜力。尽管面临挑战，Cawachi 的每股收益在过去三年中年均增长 5.5%，显示出其潜在的实力。然而，投资者在考虑 Cawachi 的股票之前，应注意两个警示信号</p>

<p>The market seemed underwhelmed by last week's earnings announcement from <strong>Cawachi Limited</strong> (TSE:2664) despite the healthy numbers. We did some analysis to find out why and believe that investors might be missing some encouraging factors contained in the earnings.</p>
<div class="lb-trans"><p>尽管 <strong>Cawachi Limited</strong>（东京证券交易所代码：2664）上周的财报数据良好，但市场似乎对此反应平平。我们进行了一些分析，试图找出原因，并认为投资者可能忽视了财报中一些令人鼓舞的因素。</p>
</div><p>AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.</p>
<div class="lb-trans"><p>人工智能即将改变医疗保健。这 20 只股票正在从早期诊断到药物发现等各个方面进行研发。最棒的是——它们的市值都在 100 亿美元以下——现在仍然有机会提前布局。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/5478544-earnings-and-revenue-history-1-dark-2/1762379223725" alt="" original-src="https://images.simplywall.st/asset/chart/5478544-earnings-and-revenue-history-1-dark-2/1762379223725"/></p>
<p>TSE:2664 Earnings and Revenue History November 5th 2025</p>
<div class="lb-trans"><p>东京证券交易所：2664 财报和收入历史 2025 年 11 月 5 日</p>
</div><h2>The Impact Of Unusual Items On Profit</h2>
<div class="lb-trans"><h2>非常规项目对利润的影响</h2>
</div><p>Importantly, our data indicates that Cawachi's profit was reduced by JP¥1.2b, due to unusual items, over the last year. While deductions due to unusual items are disappointing in the first instance, there is a silver lining. We looked at thousands of listed companies and found that unusual items are very often one-off in nature. And, after all, that's exactly what the accounting terminology implies. Assuming those unusual expenses don't come up again, we'd therefore expect Cawachi to produce a higher profit next year, all else being equal.</p>
<div class="lb-trans"><p>重要的是，我们的数据表明，Cawachi 去年的利润因非常规项目减少了 12 亿日元。虽然由于非常规项目的扣除在第一时间令人失望，但也有积极的一面。我们查看了数千家上市公司，发现非常规项目通常是一次性的。而且，毕竟，这正是会计术语所暗示的。假设这些非常规支出不会再次出现，我们因此预计 Cawachi 明年的利润会更高，其他条件不变。</p>
</div><p><strong>Note:</strong> we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Cawachi.</p>
<div class="lb-trans"><p><strong>注意：</strong> 我们始终建议投资者检查资产负债表的强度。点击这里查看我们对 Cawachi 的资产负债表分析。</p>
</div><h2>Our Take On Cawachi's Profit Performance</h2>
<div class="lb-trans"><h2>我们对 Cawachi 利润表现的看法</h2>
</div><p>Unusual items (expenses) detracted from Cawachi's earnings over the last year, but we might see an improvement next year. Based on this observation, we consider it likely that Cawachi's statutory profit actually understates its earnings potential! And the EPS is up 5.5% annually, over the last three years. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. If you want to do dive deeper into Cawachi, you'd also look into what risks it is currently facing. To help with this, we've discovered <strong>2 warning signs</strong> (1 shouldn't be ignored!) that you ought to be aware of before buying any shares in Cawachi.</p>
<div class="lb-trans"><p>非常规项目（支出）在过去一年中削弱了 Cawachi 的收益，但我们可能会在明年看到改善。基于这一观察，我们认为 Cawachi 的法定利润实际上低估了其盈利潜力！而且过去三年每股收益年增长 5.5%。当然，在分析其收益时，我们才刚刚开始；还可以考虑利润率、预测增长和投资回报等其他因素。如果你想更深入地了解 Cawachi，还需要关注它目前面临的风险。为此，我们发现了 <strong>2 个警示信号</strong>（其中 1 个不容忽视！），在购买 Cawachi 的任何股票之前，你应该了解这些。</p>
</div><p>This note has only looked at a single factor that sheds light on the nature of Cawachi's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. Some people consider a high return on equity to be a good sign of a quality business. So you may wish to see this <strong>free</strong> collection of companies boasting high return on equity, or this list of stocks with high insider ownership.</p>
<div class="lb-trans"><p>这份报告仅关注了一个因素，揭示了 Cawachi 利润的性质。但如果你能够专注于细节，总会有更多的发现。有些人认为高股本回报率是优质企业的良好标志。因此，你可能希望查看这份 <strong>免费</strong> 的高股本回报率公司集合，或这份高内部持股的股票列表。</p>
</div>

Cawachi（TSE:2664）的收益似乎前景可期